‘Inspirational’ Dr Jane Osbourn to chair Mogrify board
Dr Jane Osbourn has been appointed chair of the board at Mogrify, a finalist in the Cambridge Independent Science and Technology Awards.
Dr Osbourn will also become a member of the scientific advisory board and support the company’s executive team in therapeutic program selection, industrial partner development, mentoring and investor relations.
Most recently, Dr Osbourn was vice president for research and development and site leader at MedImmune – formerly Cambridge Antibody Technology (CAT), and now AstraZeneca – where she contributed to the development of phage display technology.
She was made an Officer of the Order of the British Empire (OBE) in the Queen’s birthday honours this year for services to human monoclonal antibody drug research and development and biotechnology.
She said: “Mogrify’s leadership team is of high commercial and scientific calibre; it was founded by leading academics in bioinformatics, machine learning and cell reprograming, and the company has continued to strengthen its management and scientific teams with its recent move to state-of-the-art facilities on Cambridge Science Park.
“Mogrify’s platform has the ability to address many of the current challenges of cell therapy, which is an area of significant innovation and opportunity, and I am very excited to join the company at this stage in its development and look forward to its continued success.”
Mogrify CEO Dr Darrin Disley said: “Dr Osbourn is an inspirational leader in our industry who has developed numerous life-saving therapies and is renowned for her expertise in drug discovery and development among the global biotech and pharma communities.
“As chair, her guidance will be invaluable to Mogrify as we build a scalable infrastructure and the capability to develop novel cell therapies addressing musculoskeletal, auto-immune, cancer immunotherapy, ocular and respiratory diseases as well as generating and licensing novel IP related to cell conversions that exhibit safety, efficacy and scalable manufacturing profiles suitable for development as cell therapies.”
More by this authorMike Scialom